ProCE Banner Activity

Considerations in Selecting Therapy for Previously Treated CLL

Slideset

Download this slideset from a live symposium at ASH 2024 for expert perspectives on best practices in treating patients with relapsed/refractory CLL.

Released: December 04, 2024

Expiration: December 03, 2025

Share

Faculty

Danielle M. Brander

Danielle M. Brander, MD

Associate Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Department of Medicine, Duke University
Director, CLL/Lymphoma Research
Duke Cancer Institute
Durham, North Carolina

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeiGene, and Lilly.

AstraZeneca

BeiGene

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner